Glenmark Pharmaceuticals outlays Rs 700 crore capex plan for FY25 to boost growth

Operationally, Glenmark is targeting an EBITDA margin of approximately 19 percent. The company is also eyeing a double-digit profit after tax (PAT) margin while focusing on sustainable financial performance to provide value to stakeholders.
Read The Rest at :